

## TECHNICAL SHEET IDYLLA™ MSI ASSAY



The **Idylla™ MSI Assay** is intended for the qualitative detection of a novel panel of **seven monomorphic homopolymer biomarkers** for identification of human cancers with microsatellite instability (MSI). The **Idylla™ MSI Assay** uses formalin-fixed, paraffin-embedded (FFPE) tissue sections from human cancer tissue, from which nucleic acids are liberated, PCR amplified and then analyzed by high-resolution melting detection. The **Idylla™ MSI Assay** automates the entire process from FFPE sample preparation to reporting of MSI status.

### FEATURES

Idylla™ MSI Biomarkers	
ACVR2A	2q22.3-q23.1
BTBD7	14q32.12
DIDO1	20q13.33
MRE11	11q21
RYR3	15q13.3-q14
SEC31A	4q21.22
SULF2	20q13.12
Sample Processing Control	The MSI specific software or TTP will automatically check the validity of the measured fluorescence profiles: presence of specific PCR amplicons will result in biomarker-specific fluorescence profiles, which eliminates the need for an additional sample processing control in the cartridge.

Specimen requirements	
Sample Type	FFPE tissue sections (5 to 10 µm)
Neoplastic cells	≥20%, if less macro dissection is required
Tissue area	50-600 mm <sup>2</sup> (5 µm) 25-300 mm <sup>2</sup> (10 µm)
Total turnaround time	
Time	150 minutes



Biocartis and Idylla™ are registered trademarks in Europe, the United States and other countries. The Biocartis and the Idylla trademark and logo are used trademarks owned by Biocartis. Idylla™ platform is a CE marked IVD in Europe and Idylla™ MSI Assay is for Research Use Only. Not for use in diagnostic procedures. Idylla™ is available for sale in EU, USA and many other countries. Please check availability with the local Biocartis representative. © Biocartis, October 2021